2025 Scottsdale Headache Symposium Pre-Course 2: Advanced Course: Novel Targets in Headache

 

Course Instructions

  1. AHS members have complimentary access to the recorded content within this course. All others should create a new visitor account or login as a visitor to purchase the course.
  2. Once logged in or purchased, click "Take course" to access recorded content, complete the meeting evaluation, claim CME, and download a certificate.

Target Audience

Since the inaugural meeting in 1970, the Scottsdale Headache Symposium® continues to be a successful venue for providing practical, clinical, evidence-based information on the diagnosis, management and treatment of headache patients.

Learning Objectives

At the conclusion of the program, participants will report their intention to:

  1. Describe various novel targets that are being highlighted in this section that may have potential in the treatment of migraine. These will include sphingosine-1-phosphate receptor 1 (S1PR1), adenosine A3 receptors (A3AR), and Mas-related G protein-coupled receptors (MRGPR). 
  2. Identify the expression patterns of these receptors along the trigeminal pain pathway (dural, TG, TNC, supraspinal, etc) as it relates to migraine mechanisms.
Course summary
Available credit: 
  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Participation
Course opens: 
01/12/2026
Course expires: 
01/12/2027
Cost:
$500.00

Disclosure Information

The planners and faculty for this activity did not have any relationships to disclose unless listed below. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.

PURPOSE/OBJECTIVE

This educational activity is designed to describe various novel targets that may have potential in the treatment of migraine, including sphingosine-1-phosphate receptor 1 (S1PR1), adenosine A3 receptors (A3AR), and Mas-related G protein-coupled receptors (MRGPR) and help providers identify the expression patterns of these receptors along the trigeminal pain pathway (dural, TG, TNC, supraspinal, etc) as it relates to migraine mechanisms.

ACCREDITATION STATEMENT

The American Headache Society® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The American Headache Society® designates this enduring material for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS FOR CLAIMING CME:

  • Login/create a new visitor account (when creating an account, please be sure to use the email address you used during registration for the Annual Meeting).
  • Watch the session recording.
  • Complete the post-activity evaluation. 
  • Enter the number of CME credits being claimed*.
  • Download your certificate.

*Please note: The maximum number of credits is calculated based on watching the entire session recording.

FINANCIAL DISCLOSURES

The planners and faculty for this activity did not have any relationships to disclose unless listed here. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.

DISCLOSURE OF COMMERCIAL SUPPORT

The American Headache Society® received support for the SHS2025 meeting from the following organizations:

AbbVie Inc.
Axsome Therapeutics
Lundbeck LLC.
Pfizer Inc.

BIBLIOGRAPHY

References are available within the session recording.

Available Credit

  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Participation

Price

Cost:
$500.00
Please login or register to take this course.